Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could less radiation be just as good for some throat cancers?

NCT ID NCT06239727

Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a lower dose of radiation, combined with chemotherapy and an immunotherapy drug called Camrelizumab, can control stage III nasopharyngeal cancer as well as the standard higher dose. About 593 patients whose tumors respond well to initial treatment will be randomly assigned to receive either reduced or standard radiation. The goal is to see if the lower dose reduces long-term side effects without hurting survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Camrelizumab (PD-1 blocking antibody), gemcitabine, cisplatin, and reduced-dose radiotherapy
What this could lead to
If successful, this could offer a treatment option that lowers radiation side effects while still controlling the cancer effectively.
What could go wrong
This is still an experimental approach; reduced radiation might not control the cancer as well as standard doses, and the combination with immunotherapy could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 593 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 18 Years to 65 Years; 2. Eastern Cooperative Oncology Group performance status ≤1; 3. Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma; 4. Tumor staged as Stage III (T3N0 Excepted; AJCC 8th); 5. Patients' lymph node without adverse features (no central necrosis, no muscle/skin invasion, no lymph node fusion); 6. Normal bone marrow function: white blood cell count \> 4×10\^9/L, hemoglobin \> 90g/L, platelet count \> 100×10\^9/L; 7. Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml/min; 8. Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab); 9. Plasma EBV DNA after the second cycle of concurrent chemotherapy: negative; 10. Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1); 11. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule; 12. Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment. Exclusion Criteria: 1. Hepatitis B virus surface antigen (HBsAg) positive and Hepatitis B virus DNA \> 1000 copies/ml; 2. Anti-hepatitis C virus positive; 3. Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS); 4. Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved; 5. Active, known or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchiectasis). Exceptions are type I diabetes mellitus, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment (such as vitiligo, psoriasis or alopecia); 6. Previous interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy; 7. Chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg prednisone per day) or any other form of immunosuppressive therapy. Subjects who used inhaled or topical corticosteroids were eligible; 8. Uncontrolled heart disease, for example: 1) heart failure (NYHA level ≥ 2), 2) unstable angina, 3) myocardial infarction in past 1 year, 4) supraventricular or ventricular arrhythmia requiring treatment or intervention; 9. Active infection requiring systemic treatment; 10. Previous or concurrent with other malignant tumors, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer; 11. History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma; 12. Receive treatment for the local or regional disease other than that specified in the research plan; 13. Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility); 14. Allergy to macromolecular protein preparations, or any component of Camrelizumab; 15. Receiving live vaccine within 30 days of the initial Camrelizumab; 16. Contraindications to MRI examination, for example: claustrophobia, allergy to MRI contrast; 17. History of psychotropic disease, alcoholism or drug abuse, and other situation assessed by the investigators that may compromise the safety or compliance of patients, such as serious disease requiring timely treatment (including mental illness), severe laboratory abnormalities, or family-social risk factors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Guangdong Medical University

    RECRUITING

    Zhanjiang, Guangdong, China

  • Cancer Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, China

  • Cancer Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, Guizhou, China

  • Cancer Hospital of Shantou University Medical College

    RECRUITING

    Shantou, Guangdong, China

  • Chongqing Cancer Hospital

    RECRUITING

    Chongqing, China

  • Dongguan People's Hospital

    RECRUITING

    Dongguan, Guangdong, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, China

  • Guangdong Nongken Central Hospital

    RECRUITING

    Zhanjiang, Guangdong, China

  • Hubei Province Cancer Hosiptal

    RECRUITING

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410000, China

  • Jiangsu Cancer Hospital

    RECRUITING

    Nanjing, Jiangsu, China

  • Jiangsu Provinee Hospital of Chinese Medicine

    RECRUITING

    Nanjing, Jiangsu, China

  • Jiangxi Cancer Center

    RECRUITING

    Nanchang, Jiangxi, China

  • Sichuan Cancer Hospital

    RECRUITING

    Chengdu, Sichuan, China

  • Sun Yat-Sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

  • The Affiliated Panyu Central Hospital of Guangzhou Medical University

    RECRUITING

    Guangzhou, Guangdong, 511400, China

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, Fujian, China

  • The First Affiliated Hospital of Xian Jiaotong University

    RECRUITING

    Xian, Shanxi, China

  • The First People's Hospital of Foshan

    RECRUITING

    Foshan, Guangdong, 528000, China

  • The Second Affiliated Hospital of Hainan Medical University

    RECRUITING

    Haikou, Hainan, China

  • Tianjin Medical University Cancer Institute & Hospital

    RECRUITING

    Tianjin, China

  • Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • West China Hospital，Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

  • Xiangya Hospital Central South University

    RECRUITING

    Changsha, Hunan, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.